account adjust acquisition-rel cost certain
signific item
estim top bottom line sale ep guidanc
ep estim consensu newli
issu ep guidanc ep includ neg fx impact
rais ep estim
sale forecast
consensu product beat estim includ keytruda
januvia zetia vytorin isentress singulair cubicin simponi gardasil
combin higher product estim includ zepati
light zostavax light remicad combin
forecast guidanc sale set includ fx impact
last publish estim flat
gpm estim
estim sg flat forecast net non-op
incom estim tax rate
forecast ad ep share count
keytruda full ph data nsclc met pfs/o ph ii/ data
nsclc monotherapi squamou
nsclc approv primari mediastin b-cell lymphoma
pdufa keytruda epacadostat ph data melanoma januvia
next step post apr label inclus teco data doravirin approv
hiv mono tablet fdc lamivudin tenofovir pdufa
zoster vaccin ph data immunocompromis patient lynparza w/azn ph data
regulatori file brcam ovarian cancer japan approv
eu file brcam bc eu approv ovarian cancer
steglatro eu approv monotherapi combo w/januvia metformin posit
merck note encourag strength keytruda/chemo combo
nsclc data optimist would receiv also note agent
target sting tigit pipelin vaccin move phase
dengu vaccin cytomegaloviru vaccin mention
pleas see page report import disclosur
merck competit posit line lung cancer clear posit advantag
appear finit bring data io/io combin expect
becom soc patient merck posit io/io combin less clear
merck face uncertainti well includ januvia outlook competit
market remicad zetia vytorin cubicin nasonex biosimilars/gener competit
pressur isentress zostavax uncertainti around outlook success
immun oncolog alzheim verubecestat believ risk balanc opportun
therefor remain market perform merck stock
uptak keytruda nsclc
keytruda chemo combo nsclc
keytruda data readout variou tumor
lynparza data/fil ovarian
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
